What the FDA labels say about taking them together
Aprepitant and deferasirox
Deferasirox's FDA label of January 28, 2026 names aprepitant in its drug interactions section; the aprepitant labels PlainMeds reads (3) do not name deferasirox. The deferasirox label: “Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4.”
Check it at the source: the aprepitant FDA label on DailyMed (effective July 5, 2024, Merck Sharp & Dohme LLC); the deferasirox FDA label on DailyMed (effective January 28, 2026, Novartis Pharmaceuticals Corporation).
What does the aprepitant label say about deferasirox?
Aprepitant's label (effective July 5, 2024) and its 2 other brand-application labels do not name deferasirox in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (EMEND), NDA021549 (Msd), as published by Merck Sharp & Dohme LLC, effective July 5, 2024 (SPL set 696f9e80-9cae-403b-de9e-078343ce4713), via openFDA; the full label on DailyMed
What does the deferasirox label say about aprepitant?
Deferasirox label, drug interactionsClosely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].
Source: FDA drug label (Exjade), Novartis Pharmaceuticals Corporation, effective January 28, 2026 (SPL set 3495a70c-870c-4968-940e-8baea152cf85), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aprepitant | Deferasirox | |
|---|---|---|
| Labeled for | Nausea and vomiting | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $46.42 per capsule 40 mg capsule | $1.25 per tablet 360 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once